Stimulating erythropoiesis: Future perspectives

Kidney and Blood Pressure Research

Volumn 31, Issue 4, 2008, Pages 234-246

  Mikhail, Ashraf ^a   Covic, Adrian ^c   Goldsmith, David ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c CI Parhon Hospital   (Romania)

Author keywords

Anaemia; Cytoprotection; Erythropoiesis stimulating agent; Erythropoietin

Indexed keywords

ADENOVIRUS VECTOR; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CTNO 528; ENZYME INHIBITOR; EPOETIN ZETA; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN MIMETIC ANTIBODY FUSION PROTEIN; ERYTHROPOIETIN RECEPTOR; FG 2216; FG 4592; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ERYTHROPOIETIN FUSION PROTEIN; HX 575; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; K 11706; LABRASOL; MACROGOL; MIFEPRISTONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PBI 1402; PEGYLATED ERYTHROPOIETIN; PHYCOERYTHRIN; POLYXEN; PROLYLHYDROXYLASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 1 INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; TRANSCRIPTION FACTOR GATA; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY RESPONSE; CELL DAMAGE; CHEMOSENSITIVITY; CHRONIC KIDNEY DISEASE; CHUVASH SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ERYTHROPOIESIS; EXPERIMENTAL DOG; EXPERIMENTAL RAT; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGENICITY; ISCHEMIA; KIDNEY INJURY; LIVER INJURY; LIVER METABOLISM; LOW DRUG DOSE; NEOPLASM; NERVE CELL; NEUROPROTECTION; NONHUMAN; POLYCYTHEMIA; PRIORITY JOURNAL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REPERFUSION INJURY; RETICULOCYTE COUNT; RETICULOCYTOSIS; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VIRAL GENE THERAPY;

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FORECASTING; HEMATINICS; HUMANS;

EID: 45749091473     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141928     Document Type: Review

References (76)

1. de Francisco AL, Fernandez Fresnedo G, Rodrigo E, Pinera C, Heras M, Palomar R, Ruiz JC, Arias M: Past, present and future of erythropoietin use in the elderly. Int Urol Nephrol 2002;33:187-193.
2. Silverberg DS, Wexler D, Iaina A: The role of anemia in the progression of congestive heart failure: is there a place for erythropoietin and intravenous iron? J Nephrol 2004;17:749-761.
3. Wiecek A, Mikhail A: European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v17-v20.
4. http://www.emea.europa.eu/humandocs/PDFs/EPAR/epoetinalfahexal/H-726-en6. pdf. Accessed 22/4/2008.
5. Martin KJ, on behalf of the Epoetin Delta 3001 Study Group: Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transplant 2007;22:3052-3054.
6. Kwan JT, Pratt RD, the Epoetin Delta Study Group: Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007;23:307-311.
7. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
8. Macdougall IC: CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-440.
9. Tillmann HC, Kuhn B, Kränzlin B, Sadick M, Gross J, Gretz N, Pill J: Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 2006;69:60-67.
10. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A: Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2007;81:63-69.
11. Bunn HF: New agents that stimulate erythropoiesis. Blood 2007;109:868-873. Epub 10 Oct 2006.
12. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215.
13. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators: The continuous erythropoietin receptor activator (CERA) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007;67:306-317.
14. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D, BA16260 Study Invesigators: Continuous erythropoietin receptor activator (CERA) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract 2006;60:1687-1696. Erratum in: Int J Clin Pract 2007;61:1776-1777.
15. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators: Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646.
16. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U, ARCTOS Study Investigators: CERA corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3:337-347.
17. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D: PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007;35:9-16.
18. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-464.
19. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM: Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006;108:1830-1834.
20. Macdougall I, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Sulowicz W, Zamauskaite A, Leong R, Iwashita J, Duliege AM, Wiecek A: Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), achieves correction of anemia and maintains hemoglobin (Hb) in patients with chronic kidney disease (CKD) (abstract F-FC079). J Am Soc Nephrol 2006;17:35A.
21. Johnson DL, Jolliffe LK: Erythropoietin mimetic peptides and the future. Nephrol Dial Transplant 2000;15:1274-1277.
22. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL: An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999;274:24773-24778.
23. Coscarella A, Liddi R, Bach S, Zappitelli S, Urso R, Mele A, De Santis R: Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys. Mol Biotechnol 1998;10:115-122.
24. Coscarella A, Liddi R, Di Loreto M, Bach S, Faiella A, van der Meide PH, Mele A, De Santis R: The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 1998;10:964-969.
25. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al: Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337:525-531.
26. Yeh P, Landais D, Lemaitre M, Maury I, Crenne JY, Becquart J, Murry-Brelier A, Boucher F, Montay G, Fleer R, et al: Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 1992;89:1904-1908.
27. Bugelski P, Nesspor BT, Spinka-Doms T, Markopoulos D, Eirikis E, Fisher J, Volk A, Shamberger K, James I, Fisher P, Pool C, Jang H, Miller B, Huang C, Heavner G, Knight D, Ghrayeb J, Scallon B: Pharmacokinetics and pharmacodynamics of CTNO528, a novel erythropoiesis receptor agonist in normal and anaemic rats (abstract 4261). Blood 2005;106:146b.
28. Franson KL, Burggraaf, Bouman-Trio EA, Cohen AF, Miller BE, Jang H, Marciniak SL, van de Ketterij EPS, Frederick b, Jiao Q, Getsy J, Bald EH, Walker H, Schantz A, Ford JA, Mascioli K, Kowalchick JB: A phase I, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmakodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CTNO528 in healthy male subjects (abstract 4283). Blood 2005;106:146b.
29. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:449-489.
30. Semenza GL: Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-812.
31. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684.
32. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-621.
33. Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW, McMullin MF, Polyakova LA, Ang SO, Pastore YD, Jedlickova K, Lappin TR, Gordeuk V, Prchal JT: The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 2004;103:1937-1940.
34. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, Butman JA, Jedlickova K, Prchal JT, Polyakova LA: Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004;103:3924-3932.
35. Lonser RR, Glenn GM, Walther M, et al: von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
36. Clifford SC, Cockman ME, Smallwood AC, et al: Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-1038.
37. Guenzler V, Muthukrishnan E, Neumayer HH, Sacherer K, Schmidt R, Mitzner A, Wiecek A, Piecha G, Ignacy W, Scigalla P: FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease (abstract SA-PO924). J Am Soc Nephrol 2005;16:758A.
38. Klaus S, Arend M, Fourney P, Flippin L, Gervasi D, Guenzler V, Kochendoerfer G, Langsetmo I, Lin A, McDaniel D, Meier-Davis S, Seeley T, Spong S, Liu DY: Induction of erythropoiesis and iron utilization by the HIF prolyl hydroxylase inhibitor FG-4592 (abstract F-FC050). J Am Soc Nephrol 2005;16:49A.
39. Ferreira R, Ohneda K, Yamamoto M, Philipsen S: GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 2005;25:1215-1227.
40. Weiss MJ, Keller G, Orkin SH: Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994;8:1184-1197.
41. Tsai FY, Orkin SH: Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 1997;89:3636-3643.
42. Imagawa S, Yamamoto M, Miura Y: Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997;89:1430-1439.
43. Imagawa S, Tarumoto T, Suzuki N, Mukai HY, Hasegawa Y, Higuchi M, Neichi T, Ozawa K, Yamamoto M, Nagasawa T: L-Arginine rescues decreased erythropoietin gene expression by stimulating GATA-2 with L-NMMA. Kidney Int 2002;61:396-404.
44. Tarumoto T, Imagawa S, Ohmine K, Nagai T, Higuchi M, Imai N, Suzuki N, Yamamoto M, Ozawa K: N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2. Blood 2000;96:1716-1722.
45. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M: Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 2004;104:4300-4307.
46. Shen SH, Bastien L, Posner BI, Chretien P: A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the proteintyrosine kinases. Nature 1991;352:736-739. Erratum in: Nature 1991;353:868.
47. Klingmüller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Specific recruitment of SHPTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995;80:729-738.
48. Wickrema A, Chen F, Namin F, Yi T, Ahmad S, Uddin S, Chen YH, Feldman L, Stock W, Hoffman R, Platanias LC: Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 1999;27:1124-1132.
49. Akagi S, Ichikawa H, Okada T, Sarai A, Sugimoto T, Morimoto H, Kihara T, Yano A, Nakao K, Nagake Y, Wada J, Makino H: The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol 2004;15:3215-3224.
50. Barbone FP, Johnson DL, Farrell FX, Collins A, Middleton SA, McMahon FJ, Tullai J, Jolliffe LK: New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14(suppl 2):80-84.
51. Rinsch C, Dupraz P, Schneider BL, Deglon N, Maxwell PH, Ratcliffe PJ, Aebischer P: Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney Int 2002;62:1395-1401.
52. Rizzuto G, Cappelletti M, Mennuni C, Wiznerowicz M, DeMartis A, Maione D, Ciliberto G, La Monica N, Fattori E: Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000;11:1891-1900.
53. Maruyama H, Ataka K, Higuchi N, Sakamoto F, Gejyo F, Miyazaki J: Skin-targeted gene transfer using in vivo electroporation. Gene Ther 2001;8:1808-1812.
54. Osada S, Ebihara I, Setoguchi Y, Takahashi H, Tomino Y, Koide H: Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999;55:1234-1240.
55. Binley K, Askham Z, Iqball S, Spearman H, Martin L, de Alwis M, Thrasher AJ, Ali RR, Maxwell PH, Kingsman S, Naylor S: Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002;100:2406-2413.
56. Nordstrom JL: The antiprogestin-dependent Gene Switch system for regulated gene therapy. Steroids 2003;68:1085-1094.
57. Takács K, Du Roure C, Nabarro S, Dillon N, McVey JH, Webster Z, Macneil A, Bartok I, Higgins C, Gray D, Merkenschlager M, Fisher AG: The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes. Proc Natl Acad Sci USA 2004;101:16298-16303.
58. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI: Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 2002;196:303-310. Erratum in: J Exp Med 2003;197:1601.
59. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP: Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005;18:294-303.
60. Venkatesan N, Yoshimitsu J, Ohashi Y, Ito Y, Sugioka N, Shibata N, Takada K: Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs. Int J Pharm 2006;310:46-52.
61. Brines M, Cerami A: Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-250.
62. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LØ, Cerami-Hand C, Wuerth JP, Cerami A, Brines M: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6746.
63. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
64. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005;293:90-95.
65. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-339.
66. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL: Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006;5:356-361.
67. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565.
68. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005;24:4442-4449.
69. Kumar SM, Yu H, Fong D, Acs G, Xu X: Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006;16:275-283.
70. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
71. http://www.fda.gov/cder/drug/early_comm/ESA.htm. Accessed 22/4/2008.
72. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998;13:1206-1210.
73. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Ménard J: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetylseryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-844.
74. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
75. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
76. Levin A: Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007;22:309-312.